Andreas Viardot
YOU?
Author Swipe
View article: Fertility in patients with advanced-stage classic Hodgkin lymphoma treated with BrECADD versus eBEACOPP: a secondary analysis of the multicentre, randomised, parallel, open-label, phase 3 HD21 trial
Fertility in patients with advanced-stage classic Hodgkin lymphoma treated with BrECADD versus eBEACOPP: a secondary analysis of the multicentre, randomised, parallel, open-label, phase 3 HD21 trial Open
Takeda Oncology.
View article: Chemotherapy-free combination of ibrutinib and obinutuzumab for untreated advanced follicular lymphoma: results of a phase II study from the German Lymphoma Alliance
Chemotherapy-free combination of ibrutinib and obinutuzumab for untreated advanced follicular lymphoma: results of a phase II study from the German Lymphoma Alliance Open
Immunochemotherapy induces long-term response in patients with follicular lymphoma. However, toxicity of chemotherapy remains a relevant challenge. The Bruton’s tyrosine kinase inhibitor ibrutinib has shown significant activity in patients…
View article: 280 | GLOFITAMAB COMBINED WITH R‐CHOP OR POLA‐R‐CHP IN PATIENTS WITH PREVIOUSLY UNTREATED DIFFUSE LARGE B‐CELL LYMPHOMA: FINAL RESULTS FROM THE NP40126 STUDY
280 | GLOFITAMAB COMBINED WITH R‐CHOP OR POLA‐R‐CHP IN PATIENTS WITH PREVIOUSLY UNTREATED DIFFUSE LARGE B‐CELL LYMPHOMA: FINAL RESULTS FROM THE NP40126 STUDY Open
View article: 283 | A IBRUTINIB AND STANDARD IMMUNOCHEMOTHERAPY (R‐CHOEP) IN YOUNGER, HIGH‐RISK PATIENTS WITH DLBCL: A PROSPECTIVE, PHASE II STUDY OF GERMAN LYMPHOMA ALLIANCE
283 | A IBRUTINIB AND STANDARD IMMUNOCHEMOTHERAPY (R‐CHOEP) IN YOUNGER, HIGH‐RISK PATIENTS WITH DLBCL: A PROSPECTIVE, PHASE II STUDY OF GERMAN LYMPHOMA ALLIANCE Open
View article: 157 | PET GUIDED OMISSION OF RADIOTHERAPY IN ELDERLY DLBCL PTS WITH LESS FAVOURABLE PROGNOSIS IS SAFE: RESULTS OF 863 PATIENTS TREATED IN THE OPTIMAL > 60 TRIAL OF THE DSHNHL/GLA
157 | PET GUIDED OMISSION OF RADIOTHERAPY IN ELDERLY DLBCL PTS WITH LESS FAVOURABLE PROGNOSIS IS SAFE: RESULTS OF 863 PATIENTS TREATED IN THE OPTIMAL > 60 TRIAL OF THE DSHNHL/GLA Open
View article: 7 | POLATUZUMAB VEDOTIN, RITUXIMAB, GEMCITABINE AND OXALIPLATIN (POLA‐R‐GEMOX) FOR RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): PHASE III POLARGO TRIAL
7 | POLATUZUMAB VEDOTIN, RITUXIMAB, GEMCITABINE AND OXALIPLATIN (POLA‐R‐GEMOX) FOR RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): PHASE III POLARGO TRIAL Open
View article: 156 | EXCELLENT OUTCOME WITH INTERIM PET ADAPTED TREATMENT REDUCTION IN ELDERLY DLBCL PTSWITH FAVOURABLE PROGNOSIS: RESULTS OF 288 PTS TREATED IN OPTIMAL > 60 OF THE DSHNHL/GLA
156 | EXCELLENT OUTCOME WITH INTERIM PET ADAPTED TREATMENT REDUCTION IN ELDERLY DLBCL PTSWITH FAVOURABLE PROGNOSIS: RESULTS OF 288 PTS TREATED IN OPTIMAL > 60 OF THE DSHNHL/GLA Open
View article: 138 | PHASE 2 ELARA TRIAL 4‐YEAR UPDATE: CLINICAL OUTCOMES OF TISAGENLECLEUCEL IN PATIENTS (PTS) WITH HIGH‐RISK RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (R/R FL)
138 | PHASE 2 ELARA TRIAL 4‐YEAR UPDATE: CLINICAL OUTCOMES OF TISAGENLECLEUCEL IN PATIENTS (PTS) WITH HIGH‐RISK RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (R/R FL) Open
View article: Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed/refractory large B-cell lymphoma
Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed/refractory large B-cell lymphoma Open
Patients with large B-cell lymphoma (LBCL) who experience relapsed disease after CD19-directed chimeric antigen receptor (CAR) T-cell (CAR-T) therapy have a poor prognosis. Bispecific antibodies (BsAbs) induce complete remissions in ∼35% o…
View article: Safety and efficacy of glofitamab for relapsed/refractory large B-cell lymphoma in a multinational real-world study
Safety and efficacy of glofitamab for relapsed/refractory large B-cell lymphoma in a multinational real-world study Open
Glofitamab, a bispecific antibody targeting CD20 and CD3, is approved for relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) after at least 2 prior treatment lines, but real-world data are scarce. In this retrospective, multicen…
View article: Outcome of Patients with Hematologic or Molecular Relapsed/Refractory (R/R) Acute T- Lymphoblastic Leukemia - Data from the GMALL Study Group
Outcome of Patients with Hematologic or Molecular Relapsed/Refractory (R/R) Acute T- Lymphoblastic Leukemia - Data from the GMALL Study Group Open
Background Outcomes of newly diagnosed T-ALL has improved considerably (Gökbuget et al, ASH 2023). However, options in patients (pts) with hematological (hem) refractory/relapsed (R) disease are limited and outcomes are poor, whereas the p…
View article: Real World Patient Diagnostic and Treatment Patterns in Marginal Zone Lymphoma (MZL): First Results of the Prospective National MZL Registry of the German Lymphoma Alliance
Real World Patient Diagnostic and Treatment Patterns in Marginal Zone Lymphoma (MZL): First Results of the Prospective National MZL Registry of the German Lymphoma Alliance Open
Background: Despite being the third most frequent B-cell lymphoma, marginal zone lymphoma (MZL) has been largely underrepresented in prospective clinical trials and registries. Based on this we initiated a prospective publicly funded regis…
View article: Time of CAR-T Failure Is a Strong Predictor of Outcome for Bispecific Antibody Therapy in Relapsed/Refractory Large B-Cell Lymphoma
Time of CAR-T Failure Is a Strong Predictor of Outcome for Bispecific Antibody Therapy in Relapsed/Refractory Large B-Cell Lymphoma Open
Introduction Patients (pts) with relapsed or refractory (r/r) large B-cell lymphoma (LBCL) after CD19 chimeric antigen receptor (CAR)-T cell therapy are challenging to treat. CD20xCD3 T-cell-engaging bispecific antibodies (BsAbs) have emer…
View article: Long-Term Follow-Up of the Prospective Randomized AATT Study (Autologous or Allogeneic Transplantation in Patients With Peripheral T-Cell Lymphoma)
Long-Term Follow-Up of the Prospective Randomized AATT Study (Autologous or Allogeneic Transplantation in Patients With Peripheral T-Cell Lymphoma) Open
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. …
View article: Author Correction: Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study
Author Correction: Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study Open
View article: Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study
Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study Open
View article: Measurable residual disease quantification in adult patients with KMT2A-rearranged acute lymphoblastic leukemia
Measurable residual disease quantification in adult patients with KMT2A-rearranged acute lymphoblastic leukemia Open
In adult ALL, 5-10% of patients show KMT2A translocations (KMT2A rearrangements) with only a few secondary alterations, implicating it as a leukemia-initiating factor [1,2].Approximately 95% of all fusions in adult ALL are KMT2A::AFF1 or K…
View article: Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update
Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update Open
Tisagenlecleucel is approved for adults with relapsed/refractory (r/r) follicular lymphoma (FL) in the third- or later-line setting. The primary analysis (median follow-up, 17 months) of the phase 2 ELARA trial reported high response rates…
View article: Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma
Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma Open
View article: CT-564 ELARA Trial Update: Long-Term Clinical Outcomes and Correlative Efficacy Analyses of Tisagenlecleucel in Patients With Relapsed/Refractory Follicular Lymphoma (R/R FL)
CT-564 ELARA Trial Update: Long-Term Clinical Outcomes and Correlative Efficacy Analyses of Tisagenlecleucel in Patients With Relapsed/Refractory Follicular Lymphoma (R/R FL) Open
View article: S114: OUTCOME OF OLDER PATIENTS (>55 YRS) WITH NEWLY DIAGNOSED PH/BCR:ABL POSITIVE ALL PROSPECTIVELY TREATED ACCORDING TO PEDIATRIC-BASED, AGE-ADAPTED GMALL PROTOCOLS
S114: OUTCOME OF OLDER PATIENTS (>55 YRS) WITH NEWLY DIAGNOSED PH/BCR:ABL POSITIVE ALL PROSPECTIVELY TREATED ACCORDING TO PEDIATRIC-BASED, AGE-ADAPTED GMALL PROTOCOLS Open
Background: Outcome in younger patients (pts) with Philadelphia-positive Acute Lymphoblastic Leukemia (Ph+ ALL) has been improved by TKI with pediatric-based therapy and stem cell transplantation (SCT). In older pts the selection of tyrosi…
View article: P355: FAVORABLE OUTCOME OF PHILADELPHIA-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA WITH IMATINIB, DOSE-REDUCED INDUCTION FOLLOWED BY ALLOGENEIC STEM CELL TRANSPLANTATION –RESULTS FROM THE GMALL TRIAL 08/13
P355: FAVORABLE OUTCOME OF PHILADELPHIA-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA WITH IMATINIB, DOSE-REDUCED INDUCTION FOLLOWED BY ALLOGENEIC STEM CELL TRANSPLANTATION –RESULTS FROM THE GMALL TRIAL 08/13 Open
Background: Phase II trials with 2nd or 3rd generation Tyrosine Kinase Inhibitors (TKI) with/without immunotherapy yield promising results in Ph+ ALL. However, Imatinib (IM) in combination with chemotherapy regimens of different intensitie…
View article: Thromboembolism after Astra Zeneca COVID-19 vaccine: Not always PF4- antibody mediated
Thromboembolism after Astra Zeneca COVID-19 vaccine: Not always PF4- antibody mediated Open
Cases of thromboembolic events in 2021 flared up the discussion about the safety of Astra Zeneca's AZD1222 vaccine. We hereby report three cases of pulmonary embolism (PE), one case of extended portal vein thrombosis, and one case of combi…
View article: Radiation and Dose-densification of R-CHOP in Primary Mediastinal B-cell Lymphoma: Subgroup Analysis of the UNFOLDER Trial
Radiation and Dose-densification of R-CHOP in Primary Mediastinal B-cell Lymphoma: Subgroup Analysis of the UNFOLDER Trial Open
UNFOLDER (NCT00278408, EUDRACT 2005-005218-19) is a phase-3 trial in patients with aggressive B-cell lymphoma and intermediate prognosis, including primary mediastinal B-cell lymphoma (PMBCL). In a 2 × 2 factorial design, patients were ran…
View article: Radiation and Dose-densification of R-CHOP in Aggressive B-cell Lymphoma With Intermediate Prognosis: The UNFOLDER Study
Radiation and Dose-densification of R-CHOP in Aggressive B-cell Lymphoma With Intermediate Prognosis: The UNFOLDER Study Open
UNFOLDER (Unfavorable Young Low-Risk Densification of R-Chemo Regimens) is an international phase-3 trial in patients 18–60 years with aggressive B-cell lymphoma and intermediate prognosis defined by age-adjusted International Prognostic I…
View article: Toxicities at one year follow‐up in patients with advanced stage classical Hodgkin Lymphoma: results from the randomized phase III HD21 trial by the German Hodgkin Study Group
Toxicities at one year follow‐up in patients with advanced stage classical Hodgkin Lymphoma: results from the randomized phase III HD21 trial by the German Hodgkin Study Group Open
Introduction: The HD21 trial compares BrECADD with eBEACOPP for the first-line treatment of advanced stage classical Hodgkin Lymphoma (AS-cHL). We previously reported a superior acute tolerability profile for BrECADD. However, persisting t…
View article: General condition and comorbidity of long-term survivors of adult acute lymphoblastic leukemia
General condition and comorbidity of long-term survivors of adult acute lymphoblastic leukemia Open
Cure rates in adult acute lymphoblastic leukemia (ALL) improved using pediatric-based chemotherapy and stem cell transplantation (SCT). However, limited data on the health condition of cured adults are available whereas pediatric data cann…
View article: Safety of AFM11 in the treatment of patients with B-cell malignancies: findings from two phase 1 studies
Safety of AFM11 in the treatment of patients with B-cell malignancies: findings from two phase 1 studies Open
Background The prognosis for patients with relapsed and/or refractory (R/R) non-Hodgkin’s lymphoma (NHL) or acute lymphoblastic leukaemia (ALL) remains poor, with existing treatments having significant side effects. Developed for the treat…
View article: First-line Treatment With Bendamustine and Rituximab for Old and Frail Patients With Aggressive Lymphoma: Results of the B-R-ENDA Trial
First-line Treatment With Bendamustine and Rituximab for Old and Frail Patients With Aggressive Lymphoma: Results of the B-R-ENDA Trial Open
The incidence of aggressive B-cell lymphomas increases with age, but for elderly or frail patients not eligible for doxorubicin-containing treatment standard therapy remains to be defined. In this prospective, multicenter, phase-2 B-R-ENDA…
View article: T002: Treatment related morbidity in patients with classical Hodgkin Lymphoma: results of the ongoing, randomized phase III HD21 Trial by The German Hodgkin Study Group
T002: Treatment related morbidity in patients with classical Hodgkin Lymphoma: results of the ongoing, randomized phase III HD21 Trial by The German Hodgkin Study Group Open
Introduction: PET-guided treatment of newly diagnosed advanced stage (AS) classical Hodgkin Lymphoma (cHL) patients with eBEACOPP (escalated doses of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procar-bazine, predniso…